In­fec­tious dis­ease biotech halts late-stage tri­al due to sub­par ef­fi­ca­cy, shares plum­met 70%

En­roll­ment for a late-stage tri­al by Cal­i­for­nia biotech AN2 Ther­a­peu­tics that was test­ing its lead drug can­di­date for My­cobac­teri­um avi­um com­plex (MAC) lung dis­ease was …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER